Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) EBITDA (2023 - 2025)

Contineum Therapeutics (CTNM) has 3 years of EBITDA data on record, last reported at -$15.2 million in Q4 2025.

  • For Q4 2025, EBITDA fell 0.7% year-over-year to -$15.2 million; the TTM value through Dec 2025 reached -$59.8 million, down 41.36%, while the annual FY2025 figure was -$59.8 million, 41.36% down from the prior year.
  • EBITDA reached -$15.2 million in Q4 2025 per CTNM's latest filing, down from -$12.7 million in the prior quarter.
  • Across five years, EBITDA topped out at $41.5 million in Q2 2023 and bottomed at -$16.1 million in Q2 2025.
  • Average EBITDA over 3 years is -$6.6 million, with a median of -$9.3 million recorded in 2024.
  • Peak YoY movement for EBITDA: plummeted 121.87% in 2024, then decreased 0.7% in 2025.
  • A 3-year view of EBITDA shows it stood at -$7.6 million in 2023, then plummeted by 98.82% to -$15.1 million in 2024, then dropped by 0.7% to -$15.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$15.2 million in Q4 2025, -$12.7 million in Q3 2025, and -$16.1 million in Q2 2025.